Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,330.00 at Jefferies Financial Group

Eli Lilly and Company (NYSE:LLY) had its price target lifted by equities researchers at Jefferies Financial Group from $1,300.00 to $1,330.00 in a research note issued to investors on Thursday,MarketScreener reports. Jefferies Financial Group’s target price indicates a potential upside of 25.48% from the company’s previous close.

Several other research analysts also recently commented on the stock. Wolfe Research reaffirmed an “outperform” rating and issued a $1,350.00 target price on shares of Eli Lilly and Company in a research note on Thursday. Leerink Partners cut their price target on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating on the stock in a report on Monday, April 27th. Wall Street Zen upgraded shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. CICC Research upped their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Finally, HSBC lowered shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their target price for the stock from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,220.37.

Eli Lilly and Company Trading Up 1.8%

Shares of NYSE LLY traded up $18.27 during midday trading on Thursday, reaching $1,059.92. The company had a trading volume of 463,327 shares, compared to its average volume of 3,154,351. The stock has a market cap of $998.17 billion, a PE ratio of 37.64, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The firm’s fifty day moving average price is $941.52 and its 200-day moving average price is $1,003.33. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the previous year, the firm earned $3.34 EPS. The business’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 35.82 earnings per share for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently modified their holdings of LLY. Maryland Capital Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $25,000. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC boosted its position in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares in the last quarter. Basso Capital Management L.P. purchased a new stake in Eli Lilly and Company in the fourth quarter worth $30,000. Finally, 10Elms LLP grew its stake in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after purchasing an additional 10 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide’s Phase 3 results showed dramatic weight loss, strengthening Lilly’s obesity pipeline and potential future sales. Article: CNBC retatrutide clears obesity trial
• Positive Sentiment: Lilly agreed to buy Engage Biologics for up to $202 million, adding non-viral DNA delivery technology and expanding its genetic medicines capabilities. Article: Yahoo Finance Engage Biologics deal
• Positive Sentiment: The company also highlighted upcoming ASCO presentations across oncology, including late-stage data for Retevmo and Verzenio, which could support the long-term pipeline narrative. Article: Lilly ASCO oncology portfolio
• Neutral Sentiment: Lilly raised $8.9 billion in debt, which adds financial flexibility for acquisitions and R&D but also increases leverage. Article: TipRanks debt offering
• Negative Sentiment: Separately, Lilly disclosed a lawsuit alleging a Trulicity rebate fraud scheme cost the company more than $200 million, creating a potential legal overhang. Article: CNBC rebate fraud lawsuit

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.